Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Assessing the Efficacy and Safety of Bortezomib Based Induction and Maintenance Therapy in Transplant Ineligible Patients

Trial Profile

A Study Assessing the Efficacy and Safety of Bortezomib Based Induction and Maintenance Therapy in Transplant Ineligible Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2018 New trial record
    • 17 Jun 2018 Interim results (n=20) of clinical observation, estimating the efficiency and safety of Bortezomib based induction and maintenance therapy in transplant ineligible patients, presented at the 23rd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top